O Brien Greene & Co. Inc Has $964,000 Stock Position in Becton, Dickinson and Company $BDX

O Brien Greene & Co. Inc lowered its position in Becton, Dickinson and Company (NYSE:BDX) by 5.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,594 shares of the medical instruments supplier’s stock after selling 314 shares during the quarter. O Brien Greene & Co. Inc’s holdings in Becton, Dickinson and Company were worth $964,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Saudi Central Bank acquired a new position in Becton, Dickinson and Company in the first quarter worth approximately $26,000. Cornerstone Planning Group LLC grew its position in Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 99 shares in the last quarter. Kelly Lawrence W & Associates Inc. CA acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth $31,000. Bank of Jackson Hole Trust raised its holdings in shares of Becton, Dickinson and Company by 85.6% during the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 95 shares in the last quarter. Finally, WPG Advisers LLC acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at $36,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $177.44 on Friday. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company has a market cap of $50.86 billion, a price-to-earnings ratio of 31.91, a PEG ratio of 1.42 and a beta of 0.25. The firm’s 50-day moving average is $187.07 and its 200-day moving average is $182.55.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The company had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. Equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.4%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

Analysts Set New Price Targets

BDX has been the topic of a number of recent analyst reports. Royal Bank Of Canada reissued a “sector perform” rating and issued a $211.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, October 16th. Morgan Stanley lifted their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Wells Fargo & Company raised their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Finally, Argus boosted their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $205.40.

Insider Buying and Selling

In other news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold a total of 1,032 shares of company stock worth $193,040 in the last three months. 0.36% of the stock is owned by company insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.